Annual Report 2022

Department of Hematopoietic Stem Cell Transplantation

Takahiro Fukuda, Sung-Won Kim, Yoshihiro Inamoto, Takashi Tanaka, Ayumu Ito, Wataru Takeda, Jun Aoki, Mizuki Watanabe

Introduction

 We specialize in patients who undergo allogeneic or autologous hematopoietic stem cell transplantation (HSCT). Our transplant units include 26 beds in ward 12B and 3 beds in ward 11A. All rooms are filtered by a central high-efficiency particulate air filtration system.

The Team and What We Do

 Seven staff physicians (Drs. Kim, Inamoto, Tanaka, Ito, Takeda, Aoki, Watanabe and Fukuda) participate in the transplant program. Pediatric patients who undergo HSCT are managed in collaboration with Dr. Ogawa, the chief of the Department of Pediatric Oncology, and other pediatricians. In fiscal 2022, a total of 92 HSCTs were performed at the 12B and 12A transplant units. The number of each type of HCST performed in fiscal 2022 is shown in Table 1. The number of patients according to disease type is shown in Table 2.

 We discuss approximately 30 HSCT inpatients and those who consulted us for indication of HSCT every week at the collaborative conference on Monday with the Departments of Hematology and Pediatric Oncology. The transplant unit is staffed by 24 nurses trained in oncology and specialized supportive care for HSCT patients. The nursing team has taken the leadership to facilitate improved care for graft-versus-host disease (GVHD), and to provide a long-term follow-up (LTFU) care and education to patients and their family members. In fiscal 2022, we saw a total of 389 patients at the LTFU clinic. We discuss all HSCT inpatients in detail among all transplant team members including physicians, nurses, pharmacists, the nutritional support team, the rehabilitation team, the mental support team, and the hematopoietic cell transplant coordinator (HCTC) every week on Friday.

Research Activities

 We started a new phase II multicenter trial to determine the safety and efficacy of PBSCT from an unrelated donor with post-transplant cyclophosphamide (PTCY) in patients with aggressive ATL in March 2021 (advanced medical care B). In August 2021, we started patient registration to a nationwide collaborative registry of patients with aggressive ATL of all age groups with AMED support. In addition, we started sample collection to a biorepository system in March 2022. By the end of March 2023, 336 patients and 118 samples were registered to the prospective study.

 We have published a nationwide cross sectional questionnaire survey on work and employment of allo-HSCT survivors (Kurosawa, J Cancer Surviv 2022). We have published a registry analysis of 1,479 patients who developed adenovirus infection after transplantation (Inamoto, Am J Hematol 2022). Furthermore, we have published a registry analysis of 413 adult patients with lymphoma who underwent cord blood transplantation (Sakatoku, Ann Hematol 2022).

 In fiscal 2022, we have published 47 articles in peer-reviewed international journals.

Education

 We have trained 4 residents to develop their clinical skills for management of HSCT patients in fiscal 2022.

Future Prospects

 Our goal is to develop optimal strategies for HSCT to achieve a cure for all patients with hematologic malignancies.

List of papers published in 2022

Journal

1. Kurosawa S, Yamaguchi T, Mori A, Matsuura T, Mori T, Tanaka M, Kondo T, Umemoto Y, Goto H, Yoshioka S, Machida S, Sato T, Katayama Y, Kato S, Shono K, Mizuno I, Fujiwara SI, Kohno A, Takahashi M, Fukuda T. Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up. J Cancer Surviv. 2022 Oct;16(5):1004-1015. doi: 10.1007/s11764-021-01092-w. Epub 2021 Aug 27. PMID: 36087061

2. Inamoto Y, Takeda W, Hirakawa T, Sakaguchi H, Nakano N, Uchida N, Doki N, Ikegame K, Katayama Y, Sawa M, Kuriyama T, Hiramoto N, Ota S, Ozawa Y, Kataoka K, Kanda Y, Hino M, Kimura T, Atsuta Y, Fukuda T, Nagafuji K. Adenovirus disease after hematopoietic cell transplantation: A Japanese transplant registry analysis. Am J Hematol. 2022 Dec;97(12):1568-1579. doi: 10.1002/ajh.26723. Epub 2022 Sep 19.

3. Ito A, Kim SW, Fukuda T. Anti-programmed cell death-1 monoclonal antibody therapy before or after allogeneic hematopoietic cell transplantation for classic Hodgkin lymphoma: a literature review. Int J Hematol. 2022 Sep;116(3):309-314. doi: 10.1007/s12185-022-03391-z. Epub 2022 Jun 2.

4. Onishi A, Fuji S, Kitano S, Maeshima AM, Tajima K, Yamaguchi J, Kawashima I, Kawajiri A, Takemura T, Ito A, Tanaka T, Okinaka K, Inamoto Y, Kurosawa S, Kim SW, Munakata W, Maruyama D, Tobinai K, Fukuda T. Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma. Ann Hematol. 2022 Apr;101(4):799-810. doi: 10.1007/s00277-022-04760-8. Epub 2022 Jan 15.

5. Fukushima T, Tanaka T, Fukushima S, Watanabe M, Aoki J, Ito A, Inamoto Y, Kim SW, Kawai A, Fukuda T. Improvement in the Physical Function and Quality of Life through Exercise and Physical Activity Intervention Using a Smartphone after Allogeneic Hematopoietic Cell Transplantation: A Case Report. Phys Ther Res. 2022;25(3):162-167. doi: 10.1298/ptr.E10196. Epub 2022 Dec 22.

6. Fukuhara S, Oshikawa-Kumade Y, Kogure Y, Shingaki S, Kariyazono H, Kikukawa Y, Koya J, Saito Y, Tabata M, Yoshifuji K, Mizuno K, Miyagi-Maeshima A, Matsushita H, Sugiyama M, Ogawa C, Inamoto Y, Fukuda T, Sugano M, Yamauchi N, Minami Y, Hirata M, Yoshida T, Kohno T, Kohsaka S, Mano H, Shiraishi Y, Ogawa S, Izutsu K, Kataoka K. Feasibility and clinical utility of comprehensive genomic profiling of hematological malignancies. Cancer Sci. 2022 Aug;113(8):2763-2777. doi: 10.1111/cas.15427. Epub 2022 Jun 17.

7. Kimura SI, Akahoshi Y, Shiratori S, Okinaka K, Harada K, Uchida N, Doki N, Ikegame K, Nakamae H, Tanaka M, Takada S, Kawakita T, Matsuoka KI, Ara T, Ota S, Sawa M, Onizuka M, Fukuda T, Atsuta Y, Kanda Y, Nakasone H. Association Between Candidemia and Noninfectious Interstitial Pneumonia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. Open Forum Infect Dis. 2023 Mar 27;10(4):ofad163.

8. Mizumaki H, Ishiyama K, Aoki J, Mori J, Mizuno S, Doki N, Fukuda T, Uchida N, Onizuka M, Tanaka M, Katayama Y, Ozawa Y, Ikegame K, Takada S, Kawakita T, Aotsuka N, Atsuta Y, Yanada M. Outcomes after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients with der(1;7)(q10;p10). EJHaem. 2022 Nov 6;4(1):251-257. doi: 10.1002/jha2.609. eCollection 2023 Feb.

9. Kamijo K, Shimomura Y, Shinohara A, Mizuno S, Kanaya M, Usui Y, Kim SW, Ara T, Mizuno I, Kuriyama T, Nakazawa H, Matsuoka KI, Kusumoto S, Maseki N, Yamaguchi M, Ashida T, Onizuka M, Fukuda T, Atsuta Y, Kondo E. Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation. Ann Hematol. 2023 Mar;102(3):651-661. doi: 10.1007/s00277-023-05084-x. Epub 2023 Jan 12.

10. Yanagisawa R, Hirakawa T, Doki N, Ikegame K, Matsuoka KI, Fukuda T, Nakamae H, Ota S, Hiramoto N, Ishikawa J, Ara T, Tanaka M, Koga Y, Kawakita T, Maruyama Y, Kanda Y, Hino M, Atsuta Y, Yabe H, Tsukada N. Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors. Int J Hematol. 2023 Mar;117(3):421-427. doi: 10.1007/s12185-022-03489-4. Epub 2022 Nov 20.

11. Nakamura Y, Mori T, Kako S, Yamazaki H, Kanda Y, Uchida N, Tanaka M, Nawa Y, Fukuda T, Ichinohe T, Atsuta Y, Onishi Y. Outcome of peripheral blood stem cell transplantation from HLA-identical sibling donors for adult patients with aplastic anemia. Int J Hematol. 2023 Mar;117(3):356-365. doi: 10.1007/s12185-022-03487-6. Epub 2022 Nov 15.

12. Shimomura Y, Komukai S, Kitamura T, Sobue T, Kurosawa S, Doki N, Katayama Y, Ozawa Y, Matsuoka KI, Tanaka T, Kako S, Sawa M, Kanda Y, Nakamae H, Nakazawa H, Ueda Y, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. Identifying the optimal conditioning intensity for stem cell transplantation in patients with myelodysplastic syndrome: a machine learning analysis. Bone Marrow Transplant. 2023 Feb;58(2):186-194. doi: 10.1038/s41409-022-01871-8. Epub 2022 Nov 14.

13. Yanada M, Yamasaki S, Konuma T, Mizuno S, Uchida N, Onai D, Fukuda T, Tanaka M, Ozawa Y, Eto T, Ikegame K, Sawa M, Katayama Y, Kawakita T, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. Int J Hematol. 2023 Mar;117(3):398-408. doi: 10.1007/s12185-022-03486-7. Epub 2022 Nov 6.

14. Konuma T, Kanda J, Uchida N, Nishijima A, Tanaka M, Ozawa Y, Sawa M, Onizuka M, Ota S, Maruyama Y, Kanda Y, Kawakita T, Ara T, Eto T, Nakamae H, Kimura T, Fukuda T, Atsuta Y; Donor/Source Working Group of theJapanese Society for Transplantation and Cellular Therapy. Intensified conditioning regimens improved disease-free survival and engraftment after unrelated single-unit cord blood transplantation but not after matched sibling or matched unrelated donor allogeneic hematopoietic cell transplantation. Hematol Oncol. 2023 Feb;41(1):147-158. doi: 10.1002/hon.3094. Epub 2022 Oct 31.

15. Konuma T, Harada K, Kondo T, Masuko M, Uchida N, Yano S, Kawakita T, Onizuka M, Ota S, Sakaida E, Miyakoshi S, Ozawa Y, Imamura Y, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japanese Society for Transplantation and Cellular Therapy. Salvage single-unit unrelated cord blood transplantation for graft failure following initial allogeneic transplantation in adult acute myeloid leukemia: trends in outcomes over the past 20 years. Bone Marrow Transplant. 2022 Dec;57(12):1848-1850. doi: 10.1038/s41409-022-01840-1. Epub 2022 Oct 4.

16. Sakatoku K, Kim SW, Okamura H, Kanaya M, Kato K, Yamasaki S, Uchida N, Kobayashi H, Fukuda T, Takayama N, Ishikawa J, Nakazawa H, Sakurai M, Ikeda T, Kondo T, Yoshioka S, Miyamoto T, Kimura T, Ichinohe T, Atsuta Y, Kondo E. Improved survival after single-unit cord blood transplantation using fludarabine and melphalan-based reduced-intensity conditioning for malignant lymphoma: impact of melphalan dose and graft-versus-host disease prophylaxis with mycophenolate mofetil. Ann Hematol. 2022 Dec;101(12):2743-2757. doi: 10.1007/s00277-022-04990-w. Epub 2022 Oct 5.

17. Yanada M, Matsuda K, Ishii H, Fukuda T, Ozeki K, Ota S, Tashiro H, Uchida N, Kako S, Doki N, Kawakita T, Onishi Y, Takada S, Kondo Y, Tanaka J, Kanda Y, Atsuta Y, Yano S. Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Acute Promyelocytic Leukemia. Transplant Cell Ther. 2022 Dec;28(12):847.e1-847.e8. doi: 10.1016/j.jtct.2022.09.021. Epub 2022 Sep 28.

18. Atsuta Y, Sugita J, Nakamae H, Maruyama Y, Ishiyama K, Shiratori S, Fukuda T, Kurata M, Shingai N, Ozawa Y, Masuko M, Nagafuji K, Takada S, Kako S, Kanda Y, Kanda J, Ichinohe T, Teshima T. Comparable survival outcomes with haploidentical stem cell transplantation and unrelated bone marrow transplantation. Bone Marrow Transplant. 2022 Dec;57(12):1781-1787. doi: 10.1038/s41409-022-01822-3. Epub 2022 Sep 12.

19. Konuma T, Shimomura Y, Ishiyama K, Ara T, Nakamae H, Hiramoto N, Eto T, Maruyama Y, Nagafuji K, Ishikawa J, Uchida N, Tanaka M, Onizuka M, Ueda Y, Anzai N, Kimura T, Kanda Y, Fukuda T, Atsuta Y. Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation for myelodysplastic syndrome: A retrospective study from the Adult Myelodysplastic Syndrome Working Group of the Japanese Society for Transplantation and Cellular Therapy (JSTCT). Am J Hematol. 2022 Dec;97(12):E447-E450. doi: 10.1002/ajh.26722. Epub 2022 Sep 22.

20. Sugita J, Atsuta Y, Nakamae H, Maruyama Y, Ishiyama K, Shiratori S, Fukuda T, Kurata M, Shingai N, Ozawa Y, Masuko M, Nagafuji K, Uchida N, Tanaka M, Onizuka M, Kanda J, Kimura T, Ichinohe T, Teshima T. Comparable survival outcomes with haploidentical stem cell transplantation and cord blood transplantation. Bone Marrow Transplant. 2022 Nov;57(11):1681-1688. doi: 10.1038/s41409-022-01770-y. Epub 2022 Aug 20.

21. Konuma T, Mizuno S, Harada K, Uchida N, Takahashi S, Eto T, Ota S, Kobayashi H, Katayama Y, Mori Y, Maruyama Y, Onizuka M, Yonezawa A, Kawakita T, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japanese Society for Transplantation and Cellular Therapy. Reducing Mortality of Single-Unit Unrelated Cord Blood Transplantation for Relapsed Acute Myeloid Leukemia after a Previous Allogeneic Transplantation: A Real-World Retrospective Study Over the Past 19 Years in Japan. Transplant Cell Ther. 2022 Nov;28(11):777.e1-777.e11. doi: 10.1016/j.jtct.2022.08.006. Epub 2022 Aug 12.

22. Okada Y, Takenaka K, Murata M, Shimazu Y, Tachibana T, Ozawa Y, Uchida N, Wakayama T, Doki N, Sugio Y, Tanaka M, Masuko M, Kobayashi H, Ino K, Ishikawa J, Nakamae H, Matsuoka KI, Kanda Y, Fukuda T, Atsuta Y, Nagamura-Inoue T. Prognostic impact of complex karyotype on post-transplant outcomes of myelofibrosis. Hematol Oncol. 2022 Dec;40(5):1076-1085. doi: 10.1002/hon.3058. Epub 2022 Aug 19.

23. Mizuno S, Takami A, Kawamura K, Shimomura Y, Arai Y, Konuma T, Ozawa Y, Sawa M, Ota S, Takahashi S, Anzai N, Hiramoto N, Onizuka M, Nakamae H, Tanaka M, Murata M, Kimura T, Kanda J, Fukuda T, Atsuta Y, Yanada M. Favorable Outcome with Conditioning Regimen of Flu/Bu4/Mel in Acute Myeloid Leukemia Patients in Remission Undergoing Cord Blood Transplantation. Transplant Cell Ther. 2022 Nov;28(11):775.e1-775.e9. doi: 10.1016/j.jtct.2022.07.026. Epub 2022 Aug 1.

24. Kanda Y, Doki N, Kojima M, Kako S, Inoue M, Uchida N, Onishi Y, Kamata R, Kotaki M, Kobayashi R, Tanaka J, Fukuda T, Fujii N, Miyamura K, Mori SI, Mori Y, Morishima Y, Yabe H, Atsuta Y, Kodera Y. Effect of Cryopreservation in Unrelated Bone Marrow and Peripheral Blood Stem Cell Transplantation in the Era of the COVID-19 Pandemic: An Update from the Japan Marrow Donor Program. Transplant Cell Ther. 2022 Oct;28(10):677.e1-677.e6. doi: 10.1016/j.jtct.2022.06.022. Epub 2022 Jul 6.

25. Morita-Fujita M, Arai Y, Kondo T, Harada K, Uchida N, Toya T, Ozawa Y, Fukuda T, Ota S, Onizuka M, Kanda Y, Maruyama Y, Takada S, Kawakita T, Ara T, Ichinohe T, Kimura T, Atsuta Y, Kako S. Adult patients with Ph+ ALL benefit from conditioning regimen of medium-dose VP16 plus CY/TBI. Hematol Oncol. 2022 Dec;40(5):1041-1055. doi: 10.1002/hon.3046. Epub 2022 Jul 10.

26. Nishiwaki S, Akahoshi Y, Morita-Fujita M, Shimizu H, Uchida N, Ozawa Y, Fukuda T, Tanaka M, Ikegame K, Ota S, Katayama Y, Takahashi S, Kawakita T, Ara T, Onizuka M, Kimura T, Tanaka J, Atsuta Y, Arai Y. Improvements in allogeneic hematopoietic cell transplantation outcomes for adults with ALL over the past 3 decades. Blood Adv. 2022 Aug 9;6(15):4558-4569. doi: 10.1182/bloodadvances.2022008032.

27. Jo T, Arai Y, Kondo T, Mizuno S, Hirabayashi S, Inamoto Y, Doki N, Fukuda T, Ozawa Y, Katayama Y, Kanda Y, Fukushima K, Matsuoka KI, Takada S, Sawa M, Ashida T, Onizuka M, Ichinohe T, Atsuta Y, Kanda J, Yanada M. Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients. Cytotherapy. 2022 Oct;24(10):1013-1025. doi: 10.1016/j.jcyt.2022.05.009. Epub 2022 Jun 18.

28. Okada Y, Nakasone H, Konuma T, Uchida N, Tanaka M, Sugio Y, Aotsuka N, Nishijima A, Katsuoka Y, Ara T, Ota S, Onizuka M, Sawa M, Kimura T, Fukuda T, Atsuta Y, Kanda J, Kimura F. Ideal Body Weight Is Useful For Predicting Neutrophil Engraftment and Platelet Recovery for Overweight and Obese Recipients in Single-Unit Cord Blood Transplantation. Transplant Cell Ther. 2022 Aug;28(8):504.e1-504.e7. doi: 10.1016/j.jtct.2022.05.006. Epub 2022 May 13.

29. Mizuta S, Ugai T, Kato H, Doki N, Ota S, Kawakita T, Katayama Y, Kurokawa M, Nakamae H, Yano S, Nawa Y, Kanda Y, Fukuda T, Atsuta Y, Kako S. Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia. Int J Hematol. 2022 Sep;116(3):393-400. doi: 10.1007/s12185-022-03368-y. Epub 2022 May 10.

30. Harada K, Morita-Fujita M, Fukuda T, Ozawa Y, Doki N, Toyosaki M, Maruyama Y, Kanda Y, Ashida T, Eto T, Takada S, Uchida N, Ichinohe T, Kanda J, Onizuka M, Atsuta Y, Kako S, Arai Y. Overcoming minimal residual disease using intensified conditioning with medium-dose etoposide, cyclophosphamide and total body irradiation in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Cytotherapy. 2022 Sep;24(9):954-961. doi: 10.1016/j.jcyt.2022.03.004. Epub 2022 May 7.

31. Shimazu Y, Murata M, Kondo T, Minami Y, Tachibana T, Doki N, Uchida N, Ozawa Y, Yano S, Fukuda T, Kato J, Ara T, Eto T, Ishikawa J, Nakamae H, Tanaka J, Ichinohe T, Atsuta Y, Nagamura-Inoue T; working group of the Japan Society for Transplantation and Cellular Therapy. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. Hematol Oncol. 2022 Aug;40(3):442-456. doi: 10.1002/hon.3000. Epub 2022 Apr 12.

32. Sekiya T, Kasahara H, Takemura R, Fujita S, Kato J, Doki N, Katayama Y, Ozawa Y, Takada S, Eto T, Fukuda T, Ichinohe T, Takanashi M, Onizuka M, Atsuta Y, Okamoto S, Yoshimura A, Takaki S, Mori T. Essential Roles of the Transcription Factor NR4A1 in Regulatory T Cell Differentiation under the Influence of Immunosuppressants. J Immunol. 2022 May 1;208(9):2122-2130. doi: 10.4049/jimmunol.2100808. Epub 2022 Apr 6.

33. Kameda K, Kako S, Kim SW, Usui Y, Kato K, Fukuda T, Uchida N, Kobayashi H, Wakayama T, Sakaida E, Yano S, Imada K, Nara M, Ikeda T, Fuchida SI, Ishikawa J, Sugahara H, Kanda J, Kimura T, Ichinohe T, Atsuta Y, Kondo E. Autologous or allogeneic hematopoietic cell transplantation for relapsed or refractory PTCL-NOS or AITL. Leukemia. 2022 May;36(5):1361-1370. doi: 10.1038/s41375-022-01545-w. Epub 2022 Mar 28. PMID: 35347237

34. Mizuno S, Takami A, Takamatsu H, Hanamura I, Shimazu Y, Hangaishi A, Tsukada N, Kako S, Kikuchi T, Ota S, Shimizu H, Iida S, Yoshioka S, Sawa M, Fukuda T, Kanda Y, Atsuta Y, Kawamura K. Autologous hematopoietic cell transplantation for myeloma patients with hepatitis B virus or hepatitis C virus in the era of novel agents. Bone Marrow Transplant. 2022 May;57(5):846-848. doi: 10.1038/s41409-022-01640-7. Epub 2022 Mar 24.

35. Yamamoto M, Sato M, Onishi Y, Sasahara Y, Sano H, Masuko M, Nakamae H, Matsuoka KI, Ara T, Washio K, Onizuka M, Watanabe K, Takahashi Y, Hirakawa T, Nishio M, Sakashita C, Kobayashi T, Sawada A, Ichinohe T, Fukuda T, Hashii Y, Atsuta Y, Arai A. Registry data analysis of hematopoietic stem cell transplantation on systemic chronic active Epstein-Barr virus infection patients in Japan. Am J Hematol. 2022 Jun 1;97(6):780-790. doi: 10.1002/ajh.26544. Epub 2022 Mar 30.

36. Kaito S, Kurosawa S, Najima Y, Sakaida E, Shingai N, Fukuda T, Tachibana T, Uchida N, Ozawa Y, Sawa M, Nakazawa H, Ota S, Kato J, Nakamae H, Katayama Y, Eto T, Tanaka J, Kanda Y, Atsuta Y, Arai Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Allogeneic Hematopoietic Stem Cell Transplantation for Adult Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia in Second Complete Remission. Transplant Cell Ther. 2022 Jun;28(6):326.e1-326.e10. doi: 10.1016/j.jtct.2022.03.017. Epub 2022 Mar 17.

37. Itonaga H, Kida M, Hamamura A, Uchida N, Ozawa Y, Fukuda T, Ueda Y, Kataoka K, Katayama Y, Ota S, Matsuoka KI, Kondo T, Eto T, Kanda J, Ichinohe T, Atsuta Y, Miyazaki Y, Ishiyama K. Outcome of therapy-related myelodysplastic syndrome and oligoblastic acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: A propensity score matched analysis. Hematol Oncol. 2022 Oct;40(4):752-762. doi: 10.1002/hon.2991. Epub 2022 Apr 5.

38. Tachibana T, Kondo T, Uchida N, Doki N, Takada S, Takahashi S, Yano S, Mori T, Kohno A, Kimura T, Fukuda T, Atsuta Y, Nagamura-Inoue T; Adult-CMLMPN-working-group-of-the-Japanese-Society-for-Transplantation-and-Cellular-Therapy. The Clinical Significance of BCR-ABL1 Mutations in Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Jun;28(6):321.e1-321.e8. doi: 10.1016/j.jtct.2022.03.009. Epub 2022 Mar 13.

39. Kurosawa S, Shimomura Y, Itonaga H, Najima Y, Kobayashi T, Ozawa Y, Kanda Y, Kako S, Kawakita T, Matsuoka KI, Maruyama Y, Ota S, Nakazawa H, Imada K, Kimura T, Kanda J, Fukuda T, Atsuta Y, Ishiyama K. Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis. Transplant Cell Ther. 2022 Jun;28(6):323.e1-323.e9. doi: 10.1016/j.jtct.2022.03.011. Epub 2022 Mar 13.

40. Onizuka M, Fujii N, Nakasone H, Ogata M, Atsuta Y, Suzuki R, Uchida N, Ohashi K, Ozawa Y, Eto T, Ikegame K, Nakamae H, Inoue M, Fukuda T; Transplant Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation. Risk factors and prognosis of non-infectious pulmonary complications after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022 Apr;115(4):534-544. doi: 10.1007/s12185-021-03282-9. Epub 2022 Jan 28.

41. Kimura SI, Kameda K, Harada K, Saburi M, Okinaka K, Shinohara A, Uchida N, Nishijima A, Ozawa Y, Tanaka M, Kuriyama T, Katayama Y, Sawa M, Ikegame K, Kawakita T, Kanda Y, Nakamae H, Ara T, Kimura T, Sato A, Fukuda T, Atsuta Y, Nakasone H. Risk and Predictive Factors for Candidemia After Allogeneic Hematopoietic Cell Transplantation: JSTCT Transplant Complications Working Group. Transplant Cell Ther. 2022 Apr;28(4):209.e1-209.e9. doi: 10.1016/j.jtct.2021.12.020. Epub 2022 Jan 5.

42. Shimomura Y, Sobue T, Hirabayashi S, Kondo T, Mizuno S, Kanda J, Fujino T, Kataoka K, Uchida N, Eto T, Miyakoshi S, Tanaka M, Kawakita T, Yokoyama H, Doki N, Harada K, Wake A, Ota S, Takada S, Takahashi S, Kimura T, Onizuka M, Fukuda T, Atsuta Y, Yanada M. Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia. 2022 Apr;36(4):1132-1138. doi: 10.1038/s41375-021-01474-0. Epub 2021 Nov 24. PMID: 34815516

43. Lee CJ, Wang T, Chen K, Arora M, Brazauskas R, Spellman SR, Kitko C, MacMillan ML, Pidala JA, Auletta JJ, Badawy SM, Bhatt N, Bhatt VR, Cahn JY, DeFilipp Z, Diaz MA, Farhadfar N, Gadalla S, Gale RP, Hashem H, Hashmi S, Hematti P, Hong S, Hossain NM, Inamoto Y, Lekakis LJ, Modi D, Patel S, Sharma A, Solomon S, Couriel DR. Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy. Transplant Cell Ther. 2022 Oct;28(10):712.e1-712.e8. doi: 10.1016/j.jtct.2022.07.014. Epub 2022 Jul 18.

44. Sakai T, Uchida T, Iwama S, Sugisaki K, Yamada M, Inamoto Y, Oda T. Chronic Graft-versus-host Disease-associated Membranous Nephropathy Following Bone Marrow Transplantation, Successfully Treated with Rituximab. Intern Med. 2023 Jan 15;62(2):269-273. doi: 10.2169/internalmedicine.9655-22. Epub 2022 Jun 21.

45. Cuvelier GDE, Schoettler M, Buxbaum NP, Pinal-Fernandez I, Schmalzing M, Distler JHW, Penack O, Santomasso BD, Zeiser R, Angstwurm K, MacDonald KPA, Kimberly WT, Taylor N, Bilic E, Banas B, Buettner-Herold M, Sinha N, Greinix HT, Pidala J, Schultz KR, Williams KM, Inamoto Y, Cutler C, Griffith LM, Lee SJ, Sarantopoulos S, Pavletic SZ, Wolff D. Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force. Transplant Cell Ther. 2022 Aug;28(8):426-445. doi: 10.1016/j.jtct.2022.05.038. Epub 2022 May 31.

46. Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A. Male-specific late effects in adult hematopoietic cell transplantation recipients: a systematic review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Bone Marrow Transplant. 2022 Jul;57(7):1150-1163. doi: 10.1038/s41409-022-01591-z. Epub 2022 May 6.

47. Murthy HS, Ahn KW, Estrada-Merly N, Alkhateeb HB, Bal S, Kharfan-Dabaja MA, Dholaria B, Foss F, Gowda L, Jagadeesh D, Sauter C, Abid MB, Aljurf M, Awan FT, Bacher U, Badawy SM, Battiwalla M, Bredeson C, Cerny J, Chhabra S, Deol A, Diaz MA, Farhadfar N, Freytes C, Gajewski J, Gandhi MJ, Ganguly S, Grunwald MR, Halter J, Hashmi S, Hildebrandt GC, Inamoto Y, Jimenez-Jimenez AM, Kalaycio M, Kamble R, Krem MM, Lazarus HM, Lazaryan A, Maakaron J, Munshi PN, Munker R, Nazha A, Nishihori T, Oluwole OO, Ortí G, Pan DC, Patel SS, Pawarode A, Rizzieri D, Saba NS, Savani B, Seo S, Ustun C, van der Poel M, Verdonck LF, Wagner JL, Wirk B, Oran B, Nakamura R, Scott B, Saber W. Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2022 Apr;28(4):187.e1-187.e10. doi: 10.1016/j.jtct.2022.01.017. Epub 2022 Jan 23.

48. Phelan R, Im A, Hunter RL, Inamoto Y, Lupo-Stanghellini MT, Rovo A, Badawy SM, Burns L, Eissa H, Murthy HS, Prasad P, Sharma A, Suelzer E, Agrawal V, Aljurf M, Baker K, Basak GW, Buchbinder D, DeFilipp Z, Grkovic LD, Dias A, Einsele H, Eisenberg ML, Epperla N, Farhadfar N, Flatau A, Gale RP, Greinix H, Hamilton BK, Hashmi S, Hematti P, Jamani K, Maharaj D, Murray J, Naik S, Nathan S, Pavletic S, Peric Z, Pulanic D, Ross R, Salonia A, Sanchez-Ortega I, Savani BN, Schechter T, Shah AJ, Smith SM, Snowden JA, Steinberg A, Tremblay D, Vij SC, Walker L, Wolff D, Yared JA, Schoemans H, Tichelli A. Male-Specific Late Effects in Adult Hematopoietic Cell Transplantation Recipients: A Systematic Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. Transplant Cell Ther. 2022 Jun;28(6):335.e1-335.e17. doi: 10.1016/j.jtct.2021.10.013. Epub 2021 Oct 29. PMID: 34757220 Free PMC article.